Actinium Pharmaceuticals (NYSE:ATNM) Downgraded by StockNews.com to Sell

Actinium Pharmaceuticals (NYSE:ATNM) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.

Several other equities analysts also recently commented on the company. B. Riley downgraded Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $16.00 to $2.00 in a research note on Wednesday, August 7th. Maxim Group dropped their target price on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Finally, HC Wainwright dropped their target price on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $11.40.

Actinium Pharmaceuticals Stock Performance

Actinium Pharmaceuticals stock traded up $0.02 during trading on Monday, hitting $1.94. The stock had a trading volume of 225,226 shares, compared to its average volume of 447,937. Actinium Pharmaceuticals has a 1 year low of $1.33 and a 1 year high of $10.24. The company’s 50 day moving average price is $1.80. The firm has a market cap of $60.53 million, a PE ratio of -1.28 and a beta of 0.14.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC bought a new position in Actinium Pharmaceuticals in the second quarter valued at $142,000. Bank of New York Mellon Corp grew its stake in shares of Actinium Pharmaceuticals by 28.3% during the second quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after buying an additional 19,035 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Actinium Pharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock worth $11,325,000 after purchasing an additional 82,113 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in shares of Actinium Pharmaceuticals during the second quarter worth about $92,000. Finally, Marshall Wace LLP boosted its holdings in shares of Actinium Pharmaceuticals by 67.9% during the second quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock worth $1,895,000 after purchasing an additional 103,557 shares during the period. Institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).